0%

est. 2Y upside i

HealthcareSeries A

Rank

#2063

Sector

Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Low

Given Stylus Medicine's early stage and high uncertainty, equity compensation carries significant risk.

Last updated: July 19, 2026

Bull (10%)+180%

Strong clinical data or partnership drives valuation to ~$1.12B (2.8x entry) net of 20% dilution. Example: successful Phase I data leading to collaboration with major pharma.

Base (55%)+30%

Steady progress with continued funding and pipeline advancement, valuation grows to ~$520M (1.3x entry) net of dilution.

Bear (35%)-100%

Clinical failure or financing difficulties lead to near-zero common equity value, given $85M preference stack.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

21%

Total funding of $85M represents 21% of estimated $400M valuation, giving preferred shareholders significant seniority.

Dilution Risk

high

Given high cash burn, additional financing likely within 2 years, potentially diluting common stock by 20% or more.

Secondary Liquidity

none

No secondary market exists; liquidity only upon IPO or acquisition.

Questions to Ask at the Interview

Strategic questions based on Stylusmedicine's data — designed to show you've done your homework.

  • 1

    “How does your recombinase platform compare to CRISPR in terms of editing efficiency and delivery?”

  • 2

    “What are the key clinical milestones expected in the next 2 years?”

  • 3

    “How do you view the competitive landscape and Stylus's differentiation?”

Community

Valuation Sentiment

Our model estimates 0% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.